Phase II evaluation of BAY 43-9006 (NSC-724772) in patients with recurrent or metastatic head and neck cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 23 Jul 2012 Actual end date (1 May 2006) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2006 Status change